Cargando…

Discovery and Development of Anti-HBV Agents and Their Resistance

Hepatitis B virus (HBV) infection is a prime cause of liver diseases such as hepatitis, cirrhosis and hepatocellular carcinoma. The current drugs clinically available are nucleot(s)ide analogues that inhibit viral reverse transcriptase activity. Most drugs of this class are reported to have viral re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyun-Hwan, Kim, Nam Doo, Seong, Baik-Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257723/ https://www.ncbi.nlm.nih.gov/pubmed/20802402 http://dx.doi.org/10.3390/molecules15095878

Ejemplares similares

Progress and Prospects of Anti-HBV Gene Therapy Development
por: Maepa, Mohube B., et al.
Publicado: (2015)

Recent Advances in the Discovery of Novel Antiprotozoal Agents
por: Lee, Seong-Min, et al.
Publicado: (2019)

The Discovery of Druggable Anti-aging Agents
por: Yalcin, Gulperi, et al.
Publicado: (2020)

Drug Discovery Study Aimed at a Functional Cure for HBV
por: Watanabe, Takehisa, et al.
Publicado: (2022)

Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents
por: Bajad, Nilesh Gajanan, et al.
Publicado: (2022)

Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria
por: Macintyre, Fiona, et al.
Publicado: (2018)

Synthesis and biological evaluation of esculetin derivatives as potential anti-HBV agents
por: Ye, Zhen, et al.
Publicado: (2023)

Serum hepatitis B virus (HBV) DNA levels at different stages of clinical course in patients with chronic HBV infection in an endemic area.
por: Heo, Jeong, et al.
Publicado: (2003)

Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment
por: Lawrenczyk, Agnieszka, et al.
Publicado: (2014)

Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
por: Kim, Yuna, et al.
Publicado: (2023)

Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics
por: Mnyandu, Njabulo, et al.
Publicado: (2021)

Antiviral Agents: Discovery to Resistance
por: Adamson, Catherine S.
Publicado: (2020)

Current Perspective in the Discovery of Anti-aging Agents from Natural Products
por: Ding, Ai-Jun, et al.
Publicado: (2017)

The Development of Sugar-Based Anti-Melanogenic Agents
por: Bin, Bum-Ho, et al.
Publicado: (2016)

Natural Products: Review for Their Effects of Anti-HBV
por: Liu, Xuqiang, et al.
Publicado: (2020)

Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics
por: Farhad, Tasneem, et al.
Publicado: (2022)

A QSAR study on some series of antihepatitis B virus (HBV) agents
por: Arora, Preet K, et al.
Publicado: (2010)

Occult HBV among Anti-HBc Alone: Mutation Analysis of an HBV Surface Gene and Pre-S Gene
por: Kim, Myeong Hee, et al.
Publicado: (2017)

Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia
por: Lee, Hyo Jeong, et al.
Publicado: (2018)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

RPS3a Over-Expressed in HBV-Associated Hepatocellular Carcinoma Enhances the HBx-Induced NF-κB Signaling via Its Novel Chaperoning Function
por: Lim, Keo-Heun, et al.
Publicado: (2011)

Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia
por: Lee, Hyo Jeong, et al.
Publicado: (2017)

Discovery and Evaluation of Thiazinoquinones as Anti-Protozoal Agents
por: Lam, Cary F. C., et al.
Publicado: (2013)

Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
por: Ahn, Soo Min, et al.
Publicado: (2022)

Anti-HBV Drugs: Progress, Unmet Needs, and New Hope
por: Kang, Lei, et al.
Publicado: (2015)

The Progress of Anti-HBV Constituents from Medicinal Plants in China
por: Geng, Chang-An, et al.
Publicado: (2018)

Advances in Molecular Diagnosis of HBV Infection and Drug Resistance
por: Sablon, Erwin, et al.
Publicado: (2005)

Monitoring the emergence of HBV resistance mutations by HBV-RNA pyrosequencing
por: Bottecchia, Marcelle, et al.
Publicado: (2015)

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities
por: Zubair, Tanzida, et al.
Publicado: (2023)

Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives
por: Taverniti, Valerio, et al.
Publicado: (2022)

Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants
por: Kim, Hong, et al.
Publicado: (2015)

The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges
por: Ge, Feilin, et al.
Publicado: (2023)

Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine
por: Painter, George R., et al.
Publicado: (2003)

A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes
por: Takamatsu, Yuki, et al.
Publicado: (2023)

Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication
por: Maeda, Kenji, et al.
Publicado: (2019)

Discovery of talmapimod analogues as polypharmacological anti-inflammatory agents
por: Liu, Wandong, et al.
Publicado: (2019)

Editorial: Advances in drug discovery for anti-Alzheimer’s agents
por: Ismaili, Lhassane
Publicado: (2022)

Pharmacokinetics of Anti-HBV Polyoxometalate in Rats
por: Wang, Juan, et al.
Publicado: (2014)

Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens
por: Gish, Robert G, et al.
Publicado: (2022)

A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria
por: Burrows, Jeremy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eb2kj3eigii59hr48150meqkh4